The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

被引:27
作者
Campbell, Jonathan D. [1 ]
Perry, Robert [1 ]
Papadopoulos, Nikolaos G. [2 ,3 ]
Krishnan, Jerry [4 ,5 ]
Brusselle, Guy [6 ,7 ,8 ]
Chisholm, Alison [9 ]
Bjermer, Leif [10 ]
Thomas, Michael [11 ]
van Ganse, Eric [12 ]
van den Berge, Maarten [13 ]
Quint, Jennifer [14 ]
Price, David [15 ,16 ]
Roche, Nicolas [17 ]
机构
[1] Univ Colorado, Ctr Pharmaceut Outcomes Res, Anschutz Med Campus, Aurora, CO 80045 USA
[2] Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece
[3] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England
[4] Univ Illinois Hosp & Hlth Sci Syst, Populat Hlth Sci Program, Chicago, IL USA
[5] Univ Illinois, Dept Med, Chicago, IL USA
[6] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium
[7] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands
[8] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands
[9] Resp Effectiveness Grp, Cambridge, England
[10] Lund Univ, Inst Clin Sci, Dept Resp Med & Allergol, Lund, Sweden
[11] Univ Southampton, Primary Care & Populat Sci, Southampton, Hants, England
[12] Univ Lyon, Pharmacoepidemiol Unit, CNRS, UMR 5558, Lyon, France
[13] Univ Groningen, Dept Pulm Dis, Univ Med Ctr Groningen, Groningen, Netherlands
[14] Imperial Coll London, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, London, England
[15] Univ Aberdeen, Acad Primary Care, Aberdeen, Scotland
[16] Observat & Pragmat Res Inst, Singapore, Singapore
[17] Univ Paris 05, EA2511, Hop Cochin, APHP, Paris, France
关键词
Asthma; Comparative effectiveness research (CER); Quality; Observational studies; Assessment tool; WORLD RESEARCH; ASTHMA; BECLOMETASONE; POPULATION; DATABASE;
D O I
10.1186/s13601-019-0256-9
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background Evidence from observational comparative effectiveness research (CER) is ranked below that from randomized controlled trials in traditional evidence hierarchies. However, asthma observational CER studies represent an important complementary evidence source answering different research questions and are particularly valuable in guiding clinical decision making in real-life patient and practice settings. Tools are required to assist in quality appraisal of observational CER to enable identification of and confidence in high-quality CER evidence to inform guideline development.Methods The REal Life EVidence AssessmeNt Tool (RELEVANT) was developed through a step-wise approach. We conducted an iterative refinement of the tool based on Task Force member expertise and feedback from pilot testing the tool until reaching adequate inter-rater agreement percentages. Two distinct pilots were conductedthe first involving six members of the Respiratory Effectiveness Group (REG) and European Academy of Allergy and Clinical Immunology (EAACI) joint Task Force for quality appraisal of observational asthma CER; the second involving 22 members of REG and EAACI membership. The final tool consists of 21 quality sub-items distributed across seven methodology domains: Background, Design, Measures, Analysis, Results, Discussion/Interpretation, and Conflict of Interest. Eleven of these sub-items are considered critical and named primary sub-items.Results Following the second pilot, RELEVANT showed inter-rater agreement 70% for 94% of all primary and 93% for all secondary sub-items tested across three rater groups. For observational CER to be classified as sufficiently high quality for future guideline consideration, all RELEVANT primary sub-items must be fulfilled. The ten secondary sub-items further qualify the relative strengths and weaknesses of the published CER evidence. RELEVANT could also be applicable to general quality appraisal of observational CER across other medical specialties.ConclusionsRELEVANT is the first quality checklist to assist in the appraisal of published observational CER developed through iterative feedback derived from pilot implementation and inter-rater agreement evaluation. Developed for a REG-EAACI Task Force quality appraisal of recent asthma CER, RELEVANT also has wider utility to support appraisal of CER literature in general (including pre-publication). It may also assist in manuscript development and in educating relevant stakeholders about key quality markers in observational CER.
引用
收藏
页数:11
相关论文
共 25 条
[1]   Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study [J].
Barnes, N. ;
Price, D. ;
Colice, G. ;
Chisholm, A. ;
Dorinsky, P. ;
Hillyer, E. V. ;
Burden, A. ;
Lee, A. J. ;
Martin, R. J. ;
Roche, N. ;
von Ziegenweidt, J. ;
Israel, E. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2011, 41 (11) :1521-1532
[2]   A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report [J].
Berger, Marc L. ;
Martin, Bradley C. ;
Husereau, Don ;
Worley, Karen ;
Allen, J. Daniel ;
Yang, Winnie ;
Quon, Nicole C. ;
Mullins, C. Daniel ;
Kahler, Kristijan H. ;
Crown, William .
VALUE IN HEALTH, 2014, 17 (02) :143-156
[3]   Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status [J].
Brusselle, Guy ;
Peche, Rudi ;
Van den Brande, Paul ;
Verhulst, Albert ;
Hollanders, Wim ;
Bruhwyler, Jacques .
RESPIRATORY MEDICINE, 2012, 106 (06) :811-819
[4]   The GRAOE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution [J].
Dreyer, Nancy A. ;
Velentgas, Priscilla ;
Westrich, Kimberly ;
Dubois, Robert .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (03) :301-U153
[5]   Adequate Levels of Adherence with Controller Medication Is Associated with Increased Use of Rescue Medication in Asthmatic Children [J].
Elkout, Hajer ;
Helms, Peter J. ;
Simpson, Colin R. ;
McLay, James S. .
PLOS ONE, 2012, 7 (06)
[6]  
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, ENCEPP CHECKL STUD P
[7]  
Global Asthma Network, 2014, GLOB ASTHM REP 2014
[8]   GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations [J].
Guyatt, Gordon H. ;
Oxman, Andrew D. ;
Vist, Gunn E. ;
Kunz, Regina ;
Falck-Ytter, Yngve ;
Alonso-Coello, Pablo ;
Schuenemann, Holger J. .
BRITISH MEDICAL JOURNAL, 2008, 336 (7650) :924-926
[9]   How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? [J].
Herland, K ;
Akselsen, JP ;
Skjonsberg, OH ;
Bjermer, L .
RESPIRATORY MEDICINE, 2005, 99 (01) :11-19
[10]   Risk Factors for Asthma-Related Healthcare Use: Longitudinal Analysis Using the NHI Claims Database in a Korean Asthma Cohort [J].
Lee, Taehoon ;
Kim, Jinhee ;
Kim, Sujeong ;
Kim, Kyoungjoo ;
Park, Yunjin ;
Kim, Yuri ;
Lee, Yoon Su ;
Kwon, Hyouk-Soo ;
Kim, Sae-Hoon ;
Chang, Yoon-Seok ;
Cho, You Sook ;
Jang, An-Soo ;
Park, Jung-Won ;
Nahm, Dong-Ho ;
Yoon, Ho-Joo ;
Cho, Sang-Heon ;
Cho, Young-Joo ;
Choi, Byoung Whui ;
Moon, Hee-Bom ;
Kim, Tae-Bum .
PLOS ONE, 2014, 9 (11)